Skip to content
★ Sign in to follow
수젠

수젠텍 Stock: price and insider trades · South Korea

KR·Mcap ₩62.1BHealth Care

No insider purchase over the last 90 days. The latest, by 오근철, was filed 20 Jul 2026.

수젠텍: what insiders have been doing

This page follows insider dealings at 수젠텍 as filed with DART (FSS), a company from the Health Care sector. The last twelve months, up to 2 November 2026, brought 4 filings signed by 3 insiders.

Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 2 board members.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 4 filings here. Our records for 수젠텍 go back to 2021, with 10 purchases and 3 sales on the open market in total.

The most recent open-market purchase was published on 20 July 2026, 111 days ago.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.

Insider Decl.
22
Thresholds
n/a
Buy Volume
€317,277
10 ops. · all time
Sell Volume
€7M
3 ops. · all time

Who traded when

BuySale
김은경1 buy
오근철1 buy

Since the insiders bought

  • Filed 08 Apr 2026 · 214 days ago · €313k
    -10.2%
    Entry ₩4,520 · Close 30 Oct 2026 ₩4,060

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 26,477 of 26,897 companies
8.5
score / 100
Value
8
Quality
10
FCF yld-26%
Earn yld-40%
EV/EBITDA·
ROE-29%
Gross mgn8.6%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩4,060
Analyst consensus
·
Income statement
Revenue₩9.4B
Gross profit₩811.1M9% margin
EBITDA-₩19.5B-208% margin
Net income-₩23.3B-235.1% margin
Valuation
Beta0.57
Balance sheet & cash
Market cap₩62.1B
Total debt₩14.5B
Free Cash Flow-₩15B
Debt / Equity21%
Profitability & ownership
ROE-29.1%
ROA-12.6%
% insiders15.1%
% institutions0.3%
Last declaration on 20 July 2026
Declarations23 total
  • Other
    Other(filed)
    0DART
  • ▲
    이사Executives(filed)
    €3,981est.0DART
    1,682 sharesShareKRXDART:20260720000345
    Canonical exit: 18 Oct 2026 (T+90)
  • ▲
    상무이사Executives
    €313kest.0DART
    98,502 sharesShareKRXDART:20260408001155
    Canonical exit: 30 Jun 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    Executives
    €894kest.0DART
    162,830 sharesKRXDART:20230707000394
  • ▲
    상무이사Executives
    0DART
    ShareKRXDART:20230707000374
    Canonical exit: 28 Sept 2023 (T+90)
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20230330000776
    Canonical exit: 28 Jun 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20221018000293
    Canonical exit: 16 Jan 2023 (T+90)
  • ▼
    Executives(filed)
    €1.8Mest.0DART
    162,830 sharesKRXDART:20220707000525
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20220707000398
    Canonical exit: 5 Oct 2022 (T+90)
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20220517000366
    Canonical exit: 15 Aug 2022 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20211119000170
    Canonical exit: 17 Feb 2022 (T+90)
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20211119000171
    Canonical exit: 17 Feb 2022 (T+90)
  • ▲
    상무이사Executives(filed)
    0DART
    ShareKRXDART:20210430001289
    Canonical exit: 29 Jul 2021 (T+90)
  • ▼
    Executives(filed)
    €4.0Mest.0DART
    162,830 sharesKRXDART:20210412003009
  • ●
    Executives
    Executives(filed)
    0DART

23 of 23 declarations

About 수젠텍

수젠텍 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative diagnostic solutions.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations